Assignee
ObsEva SA
CH·15 granted patents·12 pending applications·35 citations·filing 2014–2023
Top patents by PatentIndex Score
27 records- 0190US9670155B2Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonistsObsEva SA·Filed 2014·Granted Jun 6, 2017·12 cites·14 claims
- 0285US10555934B2Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereofObsEva SA·Filed 2017·Granted Feb 11, 2020·4 cites·60 claims
- 0384US11419851B2Oral formulations of pyrrolidine derivativesObsEva SA·Filed 2019·Granted Aug 23, 2022·1 cites·6 claims
- 0484US10047048B2Pyrrolidine derivatives as oxytocin/vasopressin V1a receptors antagonistsObsEva SA·Filed 2017·Granted Aug 14, 2018·3 cites·26 claims
- 0584US2024228439A1Pyrrolidine derivatives as oxytocin/vasopressin v1a receptors antagonistsObsEva SA·Filed 2023·Application pending·0 cites
- 0683US10478420B2Oral formulations of pyrrolidine derivativesObsEva SA·Filed 2018·Granted Nov 19, 2019·3 cites·6 claims
- 0783US9962367B2Oral formulations of pyrrolidine derivativesObsEva SA·Filed 2014·Granted May 8, 2018·5 cites·3 claims
- 0882US10604482B2Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonistsObsEva SA·Filed 2018·Granted Mar 31, 2020·2 cites·10 claims
- 0981US11759464B2Gonadotropin-releasing hormone antagonist dosing regimens for treating uterine fibroids and reducing menstrual blood lossObsEva SA·Filed 2018·Granted Sep 19, 2023·1 cites·15 claims
- 1080US9718772B2Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and methods of using the sameObsEva SA·Filed 2015·Granted Aug 1, 2017·3 cites·5 claims
- 1177US2023097933A1Pyrrolidine derivatives as oxytocin/vasopressin v1a receptors antagonistsObsEva SA·Filed 2022·Application pending·0 cites
- 1277US2023226021A1Oral formulations of pyrrolidine derivativesObsEva SA·Filed 2022·Application pending·0 cites
- 1375US11980621B2Gonadotropin-releasing hormone antagonist dosing regimens for the treatment of endometriosisObsEva SA·Filed 2018·Granted May 14, 2024·1 cites·20 claims
- 1474US2023321052A1Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereofObsEva SA·Filed 2022·Application pending·0 cites
- 1571US11312683B2Pyrrolidine derivatives as oxytocin/vasopressin via receptors antagonistsObsEva SA·Filed 2020·Granted Apr 26, 2022·0 cites·10 claims
- 1669US11534428B1Compositions and methods for delaying the incidence of laborObsEva SA·Filed 2019·Granted Dec 27, 2022·0 cites·11 claims
- 1769US11524003B2Alpha-amino esters of hydroxypropylthiazolidine carboxamide derivative and salt form, crystal polymorph thereofObsEva SA·Filed 2020·Granted Dec 13, 2022·0 cites·20 claims
- 1863US2016221944A1PYRROLIDINE DERIVATIVES AS OXYTOCIN/VASOPRESSIN V1a RECEPTORS ANTAGONISTSObsEva SA·Filed 2014·Application pending·0 cites
- 1962US2017065556A1Oral formulations of pyrrolidine derivativesObsEva SA·Filed 2014·Application pending·0 cites
- 2060US12280052B2Compositions and methods for the treatment of adenomyosis and rectovaginal endometriosisObsEva SA·Filed 2019·Granted Apr 22, 2025·0 cites·11 claims
- 2158US10752583B2Crystalline (3Z,5S)-5-(hydroxymethyl)-1-[(2′-methyl-1,1′-biphenyl-4-yl)carbonyl]pyrrolidin-3-one O-methyloxime, and methods of using the sameObsEva SA·Filed 2017·Granted Aug 25, 2020·0 cites·23 claims
- 2255US2023102503A1Biomarkers for oxytocin receptor antagonist therapyObsEva SA·Filed 2021·Application pending·0 cites
- 2349US2022305017A1Compositions and methods for the treatment of estrogen-dependent disordersObsEva SA·Filed 2020·Application pending·0 cites
- 2449US2022288154A1Gnrh antagonists for the treatment of estrogen-dependent disordersObsEva SA·Filed 2020·Application pending·0 cites
- 2549US2022323410A1Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriageObsEva SA·Filed 2020·Application pending·0 cites
- 2645US2023067378A1Compositions and methods for the treatment of estrogen-dependent disordersObsEva SA·Filed 2019·Application pending·0 cites
- 2740US2019247361A1Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriageObsEva SA·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ObsEva SA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →